This antibody gave a positive result in ELISA against the immunizing peptide. Antibody detection limit dilution 1:32,000.
Western Blot: Preliminary experiments gave an approx 35kDa band in lysates of Human Brain, Placenta and Prostate and of cell lines Daudi, HeLa and K562 after 0.1µg/ml antibody staining. Please note that currently we cannot find an explanation in the literature for the band we observe given the calculated size of 78.6kDa according to NP_000224.2. The 35kDa band was successfully blocked by incubation with the immunizing peptide.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
Gonadal and thyroid cells.
Involvement in disease
Defects in LHCGR are a cause of familial male precocious puberty (FMPP) [MIM:176410]; also known as testotoxicosis. In FMPP the receptor is constitutively activated. Defects in LHCGR are the cause of luteinizing hormone resistance (LHR) [MIM:238320]; also known as Leydig cell hypoplasia in males. LHR is an autosomal recessive disorder characterized by unresponsiveness to luteinizing hormone, defective sexual development in males, and defective follicular development and ovulation, amenorrhea and infertility in females. Two forms of the disorder have been defined in males. Type 1 is a severe form characterized by complete 46,XY male pseudohermaphroditism, low testosterone and high luteinizing hormone levels, total lack of responsiveness to luteinizing and chorionic gonadotropin hormones, lack of breast development, and absent development of secondary male sex characteristics. Type 2, a milder form, displays a broader range of phenotypic expression ranging from micropenis to severe hypospadias.
Belongs to the G-protein coupled receptor 1 family. FSH/LSH/TSH subfamily. Contains 6 LRR (leucine-rich) repeats. Contains 1 LRRNT domain.